BioSpace News Archive

Alimera Sciences, Inc. announces that it will report fourth quarter and full year 2023 financial results on March 7, 2024, prior to the market open.

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Erik Holmlin, PhD, Bionano’s president and chief executive officer, will present at TD Cowen’s 44th Annual Health Care Conference on March 6, 2024.

Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., today presented full clinical results for CNM-Au8® from the VISIONARY-MS Trial long-term open label extension (LTE) in participants with stable relapsing multiple sclerosis (RMS) totaling nearly three years of follow-up at the ninth annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum in West Palm Beach, Florida.

Achieve Life Sciences Announces Pricing of up to $124.2 Million Registered Direct Offering and Concurrent Private Placement.

Ocean Biomedical, Inc. today congratulates its joint venture partner , Virion Therapeutics, LLC for late breaker oral presentation at the upcoming 33rd Annual Meeting of APASL (The Asian Pacific Association for the Study of the Liver), taking place in Kyoto, Japan from March 27-31, 2024.

NeuroBo Pharmaceuticals, Inc. today announced that it has received first site Institutional Review Board (IRB) approval to proceed with the Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.

Agilent Technologies Inc. announced the selection of Distinguished Professors Michel Barsoum and Yury Gogotsi at Drexel University and Professor Ananda Amarasekara at Prairie View A&M University as recipients of an Agilent Solutions Innovation Research Award.

Catawba Research, a prominent global clinical research organization, welcomes Syed Faridi as its Vice President of Global Business Development.

FORE Biotherapeutics today announced the appointment of William R. Hinshaw as the Chief Executive Officer and Director of the Board.

Yield10 Bioscience, Inc. reported that its proprietary varieties of winter Camelina sativa in development responded as expected to herbicides in the first field tests conducted in the United States.